Meeting
2023 ASCO Annual Meeting
CCTG HN11: SPECT-CT guided elective contralateral neck treatment (SELECT) for patients with lateralized oropharyngeal cancer—A phase III randomized controlled trial.
Authors
John R. de Almeida
University Health Network, Toronto, ON, Canada
John R. de Almeida , Wendy R. Parulekar , Apostolos Christopoulos , Isabelle C Gauthier , Rosemary Martino , Andrea McNiven , Anthony C. Nichols , Ambika Parmar , Eitan Prisman , Jolie Ringash , Martin Smoragiewicz , Rathan M. Subramaniam , John Waldron , Steven B. Chinn , James Edward Bates , Kate Whelan , Wei Tu , Ali Hosni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT 05451004
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS6114)
DOI
10.1200/JCO.2023.41.16_suppl.TPS6114
Abstract #
TPS6114
Poster Bd #
99b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Quality of life and two-year results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (DO-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer.
First Author: Christopher Nutting
Poster
2017 ASCO Annual Meeting
Phase III randomised controlled trial (RCT) comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer (CompARE).
First Author: Hisham Mohamed Mehanna
Poster
2023 ASCO Quality Care Symposium
Quality of life comparison based on testosterone recovery after androgen deprivation therapy in patients cured from high-risk prostate cancer: Long term data from a phase III trial.
First Author: Abdenour Nabid
Poster
2023 ASCO Annual Meeting
Endpoints reported in phase 3 randomized clinical trials at ASCO 2022.
First Author: Laure-Anne Marie Nicole Teuwen